Drug
NRX-101
NRX-101 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
1
20%
Ph phase_2
3
60%
Phase Distribution
0
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(2)
Other(2)
Detailed Status
Completed2
unknown2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 23 (75.0%)
Phase 31 (25.0%)
Trials by Status
completed240%
unknown240%
not_yet_recruiting120%
Recent Activity
0 active trials
Showing 5 of 5
not_yet_recruitingphase_2
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression
NCT07227103
completedphase_2
NRX-101 for Bipolar Depression With Subacute Suicidal Ideation
NCT03395392
unknownphase_3
NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation
NCT03396068
unknown
NRX-101 Expanded Access
NCT05779267
completedphase_2
NRX101 Glx Biomarker Validation Study
NCT03402152
Clinical Trials (5)
Showing 5 of 5 trials
NCT07227103Phase 2
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression
NCT03395392Phase 2
NRX-101 for Bipolar Depression With Subacute Suicidal Ideation
NCT03396068Phase 3
NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation
NCT05779267
NRX-101 Expanded Access
NCT03402152Phase 2
NRX101 Glx Biomarker Validation Study
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5